Remove 2004 Remove Biopharma Remove Pharma Remove Safety
article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. This is reflected in the legal basis for biosimilars under Article 6 of Regulation 726/2004 and Article 10(4) of Directive 2001/83 (as amended by Directive 2004/27).

article thumbnail

The Evolution of Biosimilars from Their Beginning Until Now—And What’s Next

PM360

Now, as the President of Accord BioPharma , the U.S. This was back in 2004/2005 when we were just hearing about biosimilars for the first time and they were the great unknowns. But now the big pharma companies have also jumped into the game. specialty division of Intas Pharmaceuticals, Ltd., As an organization in the U.S.,